Follow us on Twitter
twitter icon@FreshPatents


Liver Disease patents

      

This page is updated frequently with new Liver Disease-related patent applications.




 Use of long-acting human recombinant soluble tumor necrosis factor a receptor in the preparation of drugs for preventing and treating severe liver injury on chronic liver disease patent thumbnailUse of long-acting human recombinant soluble tumor necrosis factor a receptor in the preparation of drugs for preventing and treating severe liver injury on chronic liver disease
The proposed invention involves the use of new drugs with the recombinant soluble tumor necrosis α receptor (hustnfr) and belongs to the gene engineering technology and gene function application field. This invention uses type i or type ii long-acting hustnfr (lhustnfr) to perform an intervention for severe liver injury in rats with chronic liver disease using 5 types of animal models.

 Composition for preventing and treating non-alcoholic fatty liver diseases patent thumbnailComposition for preventing and treating non-alcoholic fatty liver diseases
A composition includes a black chokeberry extract and at least one of a thistle extract, a black hoof mushroom extract and a mixture thereof. The composition is effective in preventing and treating non-alcoholic fatty liver disease caused by accumulation of fat in the liver due to excessive intake of nutrients or metabolic syndrome regardless of alcohol intake.
Jbk Natural Medicine Institute


 Method and system for treating non-alcoholic fatty liver disease patent thumbnailMethod and system for treating non-alcoholic fatty liver disease
A method and system for treating non-alcoholic fatty liver disease (nafld) involves the modulation of the gut microbial of a person suffering from nafld, and in particular the provision of a probiotic therapy configured to reduce liver aminotransferases, total-cholesterol, tnf-α and to improve insulin resistance in nafld patients.. .

 Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine patent thumbnailTreatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
Methods of treating patients suffering from non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), including those also suffering front type ii diabetes mellitus (t2dm), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.. .
Hadasit Medical Research Services And Development Ltd.


 Urea compounds and their use as enzyme inhibitors patent thumbnailUrea compounds and their use as enzyme inhibitors
Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..

 Treatment of the complications of chronic liver disease with caspase inhibitors patent thumbnailTreatment of the complications of chronic liver disease with caspase inhibitors
Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions for reducing the progression of the clinical complications associated with portal hypertension by administering the caspase inhibitors described herein..
Conatus Pharmaceuticals, Inc.


 Novel composition for nonalcoholic fatty liver disease (nafld) patent thumbnailNovel composition for nonalcoholic fatty liver disease (nafld)
The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (nash), and cirrhosis (advanced scarring of the liver)..
Cadila Healthcare Limited


 Suprametallogels and uses thereof patent thumbnailSuprametallogels and uses thereof
The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., pd(ii)-, ni(ii)-, or fe(ii)-ligand of formula (a)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers y.
Massachusetts Institute Of Technology


 Pharmaceutical composition based on a hepatoprotector and prebiotic, and  administrating patent thumbnailPharmaceutical composition based on a hepatoprotector and prebiotic, and administrating
The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses.

 Substituted amino triazoles useful as human chitinase inhibitors patent thumbnailSubstituted amino triazoles useful as human chitinase inhibitors
Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase.
Oncoarendi Therapeutics Sp. Z O.o.


Metal-particle-based oral-administrating liver-specific nucleic acid delivery system and manufacturing the same

Disclosed are a metal-nanoparticle-based liver-specific nucleic acid delivery system, a method of manufacturing the same, and a liver disease treatment composition containing the same. The liver-specific nucleic acid delivery system is coated with a bile acid-glycol chitosan polymer, so that it provides excellent liver-tissue specificity and high absorbance through digestive canals.
The Catholic University Of Korea Industry-academic Cooperation Foundation

Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling

The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (nafld), and other metabolic disorders, and various lipodystrophies such as hiv-haart induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients..
Novartis Ag

Crystallized xylose isomerase in prevention of the development of non-alcoholic fatty liver disease

The present invention relates to the composition comprising crystalline xylose-isomerase and at least one salt of a metal and/or alkaline earth metal for the treatment and prevention of non-alcoholic fatty liver disease and other fructose-related disorders.. .
Sciotec Diagnostic Technologies Gmbh

Prodrug compounds and their uses

Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver. Novel prodrug compounds of acid/alcohol derivatives such as phosphates, phosphonates, phosphonamidates, phosphoramidates, carboxylates, phenolates, and alkoxylates, their preparation and their uses are described.
Ligand Pharmaceutical, Inc.

Hepcidin mimetic peptides and uses thereof

Compounds and methods are described herein that can be used to treat subjects for conditions related to hepcidin activity, such as but not limited diseases of iron metabolism, beta thalassemia, hemochromatosis, iron-loading anemias, alcoholic liver disease, or chronic hepatitis c.. .
Merganser Biotech, Inc.

Pharmaceutical composition containing gpr119 ligand as active ingredient for preventing or treating non-alcoholic fatty liver disease

The present invention relates to a pharmaceutical composition containing a g protein coupled receptor 119 (gpr119) ligand as an active ingredient for preventing or treating non-alcoholic fatty liver disease. More particularly, it was confirmed that the gpr119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the gpr119 ligand can be useful to treat non-alcoholic fatty liver..
Snu R&db Foundation

Antibody therapeutics that bind cd147

There is disclosed compositions and methods relating to or derived from anti-cd147 antibodies. More specifically, there is disclosed fully human antibodies that bind cd147, cd147-binding fragments and derivatives of such antibodies, and cd147-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders.
Shenzhen Hightide Biopharmaceutical, Ltd.

Composition for preventing or treating fatty liver diseases

The present invention relates to a pharmaceutical composition for preventing or treating fatty liver diseases, containing (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof as active ingredients. (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof, according to the present invention, can effectively inhibit fatty liver, hepatitis and hepatic fibrosis and can be useful for preventing or treating nafld, and in particular, nash..
Lg Life Sciences Ltd.

Method to prepare ganoderma lucidum polysaccharides possessing protective activities on fatty liver disease

The present invention provides a method to prepare polysaccharides from ganoderma lucidum. The prepared polysaccharides can reduce liver weight and liver lipid content in humans and animals.
Chang Gung Biotechnology Corp.

Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and type 2 diabetes.

In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to rygb surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.. .

Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and t2d

In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to rygb surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.. .

Systems, devices and methods for performing medical procedures in the intestine

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element.
Fractyl Laboratories, Inc.

Method for assessment of hepatic function and portal blood flow

A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the stat test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate.
The Regents Of The University Of Colorado, A Body Corporate

Modulation of nlgn4 expression, nk cell activity in non-alcoholic fatty liver disease (nafld)

The present invention provides a method of diagnosing and/or monitoring a liver disorder in a subject. The method calls for isolating an immune cell population from a biological sample of the subject; and detecting expression level of an nlgn4 gene product in the immune cell population using nlgn4 specific primers or nlgn4 specific probes..
Hadasit Medical Research Services And Development Ltd.

Glucagon and glp-1 co-agonist compounds

The present invention provides glucagon and glp-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (nafld) and/or nonalcoholic steatohepatitis (nash).. .
Eli Lilly And Company

Lysosomal acid lipase therapy for nafld and related diseases

The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating the metabolic syndrome.
Children's Hospital Medical Center

Methods and compositions for modulating alpha-1 antitrypsin expression

Disclosed herein are methods for decreasing a1at mrna and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of fibrosis. Disclosed herein are methods for decreasing a1at mrna and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of liver disease, such as, a1atd associated liver disease, and pulmonary disease, such as, a1atd associated pulmonary disease in an individual in need thereof.
Ionis Pharmaceuticals, Inc.

Method to prepare hirsutella sinensis polysaccharides possessing protective activities on fatty liver disease

The present invention provides a method to prepare polysaccharides from hirsutella sinensis. The prepared polysaccharides can reduce liver size, weight and the number and size of liver lipid vacuoles, as well as serum triglycerides and serum aspartate aminotransferase levels in humans and animals.
Chang Gung Biotechnology Corp.

Compositions and methods for treating liver injury

Compositions and methods for detecting, inhibiting, treating, and/or preventing a liver disease or disorder such as cholestasis or fibrotic liver disease are provided.. .
The Children's Hospital Of Philadelphia

Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease

The present invention relates to the field of gene therapy and, more particularly, to methods for the prevention and/or treatment of non-alcoholic fatty liver disease (nafld). The viral vectors disclosed in the present invention are preferably parvoviral vector, more preferably adeno-associated vectors (aav) containing the gene encoding sirtuin 1 (sirt1) in the prevention and/or treatment of nafld.
Universitat Autònome De Barcelona

Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelithiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses.

Novel use of trimetazidine as a hepatoprotective medicine in prevention and treatment of liver diseases and conditions

This present invention discloses a new use of trimetazidine as a hepatoprotective drug in prevention and treatment of liver diseases, wherein trimetazidine is capable of inhibiting activation of resting t lymphocytes to activated lymphocytes, reducing release of cytokines, and reducing the hepatocyte injury caused by the immune system; capable of inhibiting fatty acid metabolism in hepatocytes and optimizing energy process in hepatocytes; and capable of maintaining normal function of mitochondrial permeability transition pores and reducing hepatocyte apoptosis. Clinical research and trial results suggest that, when administered to patients suffering from liver diseases and conditions, trimetazidine is capable of providing significant hepatoprotective function, and effectively decreasing transaminase levels (including alanine aminotransferase, aspartate transaminase, etc.), with such features as shortening the course of disease, reducing the mortality rate, easy and safe use, and low treatment cost.

Compositions including milk thistle and methods for the treatment of various disorders using the same

The present invention provides compositions including milk thistle or a constituent thereof for the treatment of disorders including metabolic syndrome, metabolic disorders, diabetes-related disorders, cardiovascular disorders or liver disease.. .

Somatic stem cells

Described herein is a method of treating a disorder, the method comprising: administering to a subject in need thereof a composition that contains a population of somatic stem cells that are 0.3-6.0 micrometers in size and cd9+, cd349+, cd133−, cd90−, cd34−, ssea1+, ssea4+, cd13+, or stro1+, wherein the disorder is selected from the group consisting of a neurodegenerative disease, nervous system disorder, cancer, metabolic disorder, autoimmune disorder, inflammatory disorder, heart or circulatory disorder, blood disorder, muscular dystrophy, gastrointestinal disease, kidney disease, liver disease, lung disease, adrenal disorder, a condition resulting from an injury, a condition associated with aging, and virus infection.. .
Stembios Technologies, Inc.

Various compounds as autophagy stimulants

The invention relates to promoting autophagy in the treatment or prevention of autophagy related disorders, such as various forms of cancer; liver disease, myopathies of various origin; cardiovascular disorders, neurodegenerative disorders by using the compounds of the invention or their pharmaceutically acceptable salts.. .
Velgene 3 Limited



Liver Disease topics:
  • Liver Disease
  • Fatty Liver
  • Alcoholic Fatty Liver
  • Steatohepatitis
  • Nonalcoholic Steatohepatitis
  • Hyperlipidemia
  • Liver Diseases
  • C Syndrome
  • Metabolic Syndrome
  • Insulin Resistance
  • Atherosclerosis
  • Hepatitis A
  • Pentoxifylline
  • Cilostazol
  • Amino Acid Sequence


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Liver Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Liver Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.2975

    file did exist - file did put2712

    4 - 1 - 53